Dako Gets FDA OK for HER2 Tests for Gastric, Stomach Cancer
October 21, 2010
Dako Gets FDA OK for HER2 Tests for Gastric, Stomach Cancer
The Danish firm received FDA clearance to expand the intended use of its HercepTest and HER2 FISH pharmDx Kit to include patients with metastatic gastric or stomach cancer.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- FDA Approves Dako Assays as CDx for Genentech Breast Cancer Drug
March 5, 2013 / GenomeWeb Daily News - Dako, Genentech Partner on Regulatory Submission of CDx for Second Breast Cancer Drug
May 1, 2012 / GenomeWeb Daily News - FDA Clears Dako's Companion Dx for Herceptin
December 13, 2011 / GenomeWeb Daily News - Dako, Genentech Partner on Companion Dx FDA Submission for Pertuzumab
December 9, 2011 / GenomeWeb Daily News - Dako, Genentech to Seek FDA OK on HER-2 Companion Tests for Herceptin in Gastric Cancer
August 12, 2009 / Pharmacogenomics Reporter